AVDL Research | Milton Maxwell

AVDL

Avadel Pharmaceuticals plc

21.37

-0.05-0.23%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

2.10B

P/E (TTM)

Basic EPS (TTM)

0.00

Dividend Yield

Recent Filings

8-K

Alkermes acquires Avadel

2/12/26Feb 12, 2026

Alkermes completed its acquisition of Avadel on February 12, 2026, via an Irish scheme, paying $21 cash plus $1.50 CVR per share. Avadel became Alkermes' wholly owned subsidiary, adding LUMRYZ for narcolepsy. Executives and directors departed. Trading halted; delisting follows. Prepaid $60M royalty to RTW.

8-K

Court hearing set for Avadel deal

1/20/26Jan 20, 2026

Avadel Pharmaceuticals set a High Court of Ireland hearing for February 10, 2026, to sanction its scheme of arrangement, advancing Alkermes' acquisition of all its ordinary shares announced October 22, 2025. Closure awaits court order. Interested parties must notify by February 5. Risks include deal failure.

8-K

Shareholders approve Alkermes deal

1/12/26Jan 12, 2026

Avadel shareholders overwhelmingly approved the scheme of arrangement for Alkermes' acquisition on January 12, 2026, with 97.4% of Scheme Meeting votes in favor (61.9M for, 1.6M against) and similar strong support at the EGM. Shareholders greenlit all resolutions, including articles amendment and advisory compensation. Closing awaits court and regulatory approvals. Risks persist on timely completion.

8-K

REVITALYZ enrollment complete

12/18/25Dec 18, 2025

Avadel Pharmaceuticals completed enrollment in the Phase 3 REVITALYZ trial on December 18, 2025, testing LUMRYZ as a once-nightly treatment for idiopathic hypersomnia. Data expected Q2 2026. Trial targets ESS score reduction at week 14. Forward-looking risks apply.

8-K

HSR clearance achieved

12/9/25Dec 9, 2025

Avadel's HSR waiting period expired at 11:59 p.m. on December 8, 2025, clearing a key antitrust hurdle for Alkermes' acquisition via Irish scheme of arrangement announced October 22. Closing awaits shareholder approval and Irish High Court sanction. HSR box checked. Remaining risks include vote failure or court denial.

About

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

CEO

Mr. Gregory J. Divis Jr.

IPO

6/7/1996

Website

https://www.avadel.com

Employees

188

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic